期刊文献+

多模式MRI指导的急性期脑梗死rt-PA静脉溶栓后的出血转化及相关因素分析 被引量:16

Risk of intracerebral hemorrhage following Multi-modality MRI-based intravenous thrombolytic therapy with rtPA for acute cerebral infarction
下载PDF
导出
摘要 目的探讨多模式MRI指导的颈内动脉系统急性期脑梗死患者接受重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓后发生出血转化的相关危险因素。方法对103例急性期颈内动脉系统脑梗死患者在标准时间窗(4.5h内)进行rt-PA静脉溶栓治疗。观察患者性别、年龄、吸烟、饮酒、高血压病、糖尿病、房颤、血脂、NIHSS评分及ASPECT评分与溶栓后出血的相关性。结果溶栓后发生出血转化的患者共17例,其中症状性脑出血患者有5例,占所有溶栓患者的4.85%、所有出血患者的29.41%。溶栓后脑出血与房颤、NIHSS评分及ASPECT评分均有相关性(P<0.05)。结论有房颤、NIHSS评分高及ASPECT评分低者行rt-PA静脉溶栓容易发生出血转化。 Objective To identify risk factors for intracerebral hemorrhage following Multi-modality MRI-based intravenous thrombolytic therapy with rt-PA for acute cerebral infarction in carotid territory.Methods 103 patients with acute carotid territory stroke received intravenous rt-PA within 4.5 hours of symptom onset.The factors including gender,age,smoking,alcohol,hypertension,diabetes mellitus,atrial fibrillation,blood lipids as well as NIHSS and ASPECT scores were collected to correlated with risks of intracerebral hemorrhage.Results After intravenous rt-PA administration,17 patients combined with intracerebral hemorrhage,5 patients developed symptomatic intracerebral hemorrhage account for 4.85% of overall rt-PA treated patients and 29.41% of patients with intracerebral hemorrhage respectively.Risk of recurrence of intracerebral hemorrhage was closely correlated with atrial fibrillation and scores of NHISS and ASPECT.Conclusion Overall,rt-PA treated patients with atrial fibrillation,high scores of NHISS and low scores of ASPECT had an increased risk of intracerebral hemorrhage.
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2013年第7期619-621,共3页 Journal of Apoplexy and Nervous Diseases
基金 浦东新区卫生系统重点学科建设基金(PWZXK2010-03) 浦东新区卫生系统领先人才培养基金(PWR12010-02) 上海市浦东新区卫生局项目及科技发展基金创新项目(PKJ2011-Y28 PW2011B-7) 上海市浦东新区人民医院重点学科群项目
关键词 脑梗死 颈内动脉系统 静脉溶栓 脑出血 危险因素 Cerebral infarction Carotid territory Intravenous thrombolytic Intracerebral hemorrhage Risk factors
  • 相关文献

参考文献11

  • 1Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment : pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials [ J ]. Lancet,2004,363:768 - 774.
  • 2Hacke W, Kaste M, Fieschi C,et al. Randomised double-blind place- bo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemie stroke( ECASS II). Second European-Australasian A- cute Stroke Study Investigators[J]. Laneet,1998,352:1245 -1251.
  • 3Hacke W,Kaste M,Bluhmki E,et al. ECASS investigators. Throm- bolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke[ J]. N Engl Med,2008,359:1317 - 1329.
  • 4Albers GW, Bate VE, Clark WE, et al. Intravenous tissue-type plas- minogen activator for treatment of acute stroke : the standard treatment with alteplase to reverse stroke ( STARS ) study [ J ]. JAMA, 2000, 283,1145 - 1150.
  • 5Katzan IL,Furlan AJ,Lloyd LE,et al. Use of tissue-type plasminogen activator for acute ischemic stroke:the Cleveland area experience[ J]. JAMA ,2000,288:1151 - 1158.
  • 6Nakano S, Iseda T, Kawano H, et al. Parenchymal hyperdensity on computed tomography after intra-arterial reperfusion theraphy for acute middle cerebral artery occlusion:incidence and clinical significance [ J ]. Stroke, 2001,32 ( 9 ) : 2042 - 2048.
  • 7Molina C,Montaner J,Abilleira S, et al. Timing of spontaneous reca- nalization and risk of hemorrhagic trans-formation in acute cardioem- bolic stroke[ J]. Stroke,2001,32 : 1079 - 1084.
  • 8Molina CA, Montaner J,Abilleira S, et al. Time course of tissue plas- minogen activator-induced recanalization in acute cardioembolic stroke. A case-control study[ J]. Stroke,2001,32:2821 - 2827.
  • 9Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plas- minogen activator therapy for acute ischemic stroke in clinical prac- tice : the Multicenter rt-PA Stroke Survey [ J ]. Circulation,2002,105 : 1679 - 1685.
  • 10郭义坤,李焰生.急性脑梗死患者重组组织型纤溶酶原激活物静脉溶栓后脑出血[J].国际脑血管病杂志,2010,18(2):113-118. 被引量:10

二级参考文献39

  • 1The National Institute of Netrological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischernic stroke. N Engt J Med, 1995, 333: 1581-1587.
  • 2Hacke W, Donnan G, Fieschi C, et al.ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 2004, 363: 768 -774.
  • 3Reeves MJ, Arora S, Broderick JP, et al; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke, 2005, 36: 1232-1240.
  • 4The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke, 1997, 28: 2109- 2118.
  • 5Hacke W, Kaste M, Fieschi C, etal. Rardomised double-blind placebocoutrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS H). Second European-Australasian Acute Stroke Study Investigators. Lancet, 1998, 352: 1245-1251.
  • 6Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial tbrombolysis for ischemic stroke: the PROACT Ⅱ trial. Neurology, 2001,57: 1603-1610.
  • 7Lame V, von Kummer R R, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasrninogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS Ⅱ). Stroke, 2001,32: 438-441.
  • 8Clark WM, Wissman S, Atbers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 1999, 282: 2019-2026.
  • 9Hacke W, Kaste M, Bluhmki E, et al; ECASS Invesfigators. Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke. N Engl J Med, 2008, 359: 1317-1329.
  • 10Wahlgren N, Ahmed N, Davalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (STTS- MOST): an observational study. Lancet, 2007, 369: 275-282.

共引文献9

同被引文献159

引证文献16

二级引证文献296

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部